RETRACTED: Lopsided Blood‐Thinning Drug Increases the Risk of Internal Flow Choking Leading to Shock Wave Generation Causing Asymptomatic Cardiovascular Disease

Abstract

Abstract The discovery of Sanal flow choking in the cardiovascular‐system calls for multidisciplinary and global action to develop innovative treatments and to develop new drugs to negate the risk of asymptomatic‐cardiovascular‐diseases. Herein, it is shown that when blood‐pressure‐ratio (BPR) reaches the lower‐critical‐hemorrhage‐index (LCHI) internal‐flow‐choking and shock wave generation can occur in the cardiovascular‐system, with sudden expansion/divergence/vasospasm or bifurcation regions, without prejudice to the percutaneous‐coronary‐intervention (PCI). Analytical findings reveal that the relatively high and the low blood‐viscosity are cardiovascular‐risk factors. In vitro studies have shown that nitrogen, oxygen, and carbon dioxide gases are dominant in fresh blood samples of humans/guinea pigs at a temperature range of 98.6–104 F. An in silico study demonstrated the Sanal flow choking phenomenon leading to shock‐wave generation and pressure‐overshoot in the cardiovascular‐system. It has been established that disproportionate blood‐thinning treatment increases the risk of the internal‐flow‐choking due to the enhanced boundary‐layer‐blockage‐factor, resulting from an increase in flow‐turbulence level in the cardiovascular‐system, caused by an increase in Reynolds number as a consequence of low blood‐viscosity. The cardiovascular‐risk can be diminished by concurrently lessening the viscosity of biofluid/blood and flow‐turbulence by raising the thermal‐tolerance‐level in terms of blood‐heat‐capacity‐ratio (BHCR) and/or by decreasing the systolic‐to‐diastolic blood‐pressure‐ratio.

Keywords

• acute‐heart failure
• asymptomatic hemorrhage
• BHCR
• biofluid choking
• BPR
• Covid‐19